Document is current
Any future updates will be listed below
-
Authors
Seviiri, Mathias https://orcid.org/0000-0002-8610-3283
Scolyer, Richard A. https://orcid.org/0000-0002-8991-0013
Bishop, D. Timothy https://orcid.org/0000-0002-8752-8785
Newton-Bishop, Julia A. https://orcid.org/0000-0001-9147-6802
Iles, Mark M. https://orcid.org/0000-0002-2603-6509
Lo, Serigne N. https://orcid.org/0000-0001-5092-5544
Stretch, Johnathan R.
Saw, Robyn P. M.
Nieweg, Omgo E.
Shannon, Kerwin F.
Spillane, Andrew J.
Gordon, Scott D. https://orcid.org/0000-0001-7623-328X
Olsen, Catherine M. https://orcid.org/0000-0003-4483-1888
Whiteman, David C. https://orcid.org/0000-0003-2563-9559
Landi, Maria Teresa https://orcid.org/0000-0003-4507-329X
Thompson, John F. https://orcid.org/0000-0002-2816-2496
Long, Georgina V. https://orcid.org/0000-0001-8894-3545
MacGregor, Stuart https://orcid.org/0000-0001-6731-8142
Law, Matthew H. https://orcid.org/0000-0002-4303-8821
-
Funding
Funding for this research was provided by:
National Health and Medical Research Council (APP1073898, APP1063061, APP1073898, APP1063061, APP1093017, APP1141295)
Cancer Research UK (C8216/A6129, C588/A19167, C8216/A6129, C588/A19167)
National Institutes of Health (R01 CA83115)
- License Information
-
More Information
Article History
Received: 1 August 2022
Accepted: 24 August 2022
First Online: 5 September 2022
Declarations
:
: The Melanoma Institute Australia study protocols (protocol HREC/10/RPAH/530 and HREC/11/RPAH/444) were approved by the Sydney Local Health District Ethics Review Committee, Royal Prince Alfred Hospital, Camperdown, Australia. The UK Biobank study was approved by the United Kingdom’s National North West Multi-Centre Research Ethics Committee (ref. 11/NW/0382). Leeds Melanoma Cohort approved by Northern and Yorkshire Research Ethics Committee in the United Kingdom. The Human Research Ethics Committee of QIMR Berghofer Medical Research Institute, Brisbane, Australia approved the QSkin study protocol (P1309), and this study (P2121). In all the respective studies, all participants provided written informed consent to participate.
: Not applicable.
: JFT has received honoraria for advisory board participation from BMS Australia, MSD Australia, GSK and Provectus Inc, and travel and conference support from GSK, Provectus Inc and Novartis. RAS has received fees for professional services from F. Hoffmann-La Roche Ltd, Evaxion, Provectus Biopharmaceuticals Australia, Qbiotics, Novartis, Merck Sharp & Dohme, NeraCare, AMGEN Inc., Bristol-Myers Squibb, Myriad Genetics, GlaxoSmithKline. The rest of the authors declare no conflict of interest.
